摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-chloro-benzenesulfonyl)-2-methyl-1-m-tolyl-piperazine

中文名称
——
中文别名
——
英文名称
4-(4-chloro-benzenesulfonyl)-2-methyl-1-m-tolyl-piperazine
英文别名
4-(4-Chlorophenyl)sulfonyl-2-methyl-1-(3-methylphenyl)piperazine
4-(4-chloro-benzenesulfonyl)-2-methyl-1-m-tolyl-piperazine化学式
CAS
——
化学式
C18H21ClN2O2S
mdl
——
分子量
364.896
InChiKey
UUHJXJKUAAIMSI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    49
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • N-cyclic sulfonamido inhibitors of gamma secretase
    申请人:Neitzel L. Martin
    公开号:US20060035884A1
    公开(公告)日:2006-02-16
    The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula I, wherein R 4 , R 5 , R 6 , R 7 , and R 8 , are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula I.
    本发明提供了用于治疗或预防认知障碍(如阿尔茨海默病)的 N-环磺酰胺基化合物。 特别感兴趣的化合物由式 I 定义,其中 R 4 , R 5 , R 6 , R 7 和 R 8 如说明书所述。本发明还包括由式 I 化合物组成的药物组合物,以及使用式 I 化合物治疗认知障碍(包括阿尔茨海默病)的方法。
  • N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE
    申请人:ELAN PHARMACEUTICALS, INC.
    公开号:EP1758884A2
    公开(公告)日:2007-03-07
  • [EN] N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE<br/>[FR] INHIBITEURS SULFONAMIDO N-CYCLIQUES DE GAMMA-SECRETASE
    申请人:ELAN PHARM INC
    公开号:WO2005113542A2
    公开(公告)日:2005-12-01
    The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, R7 and R8 are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer’s disease using compounds of Formula (I).
查看更多